Week in Review: Simcere Receives $503 Million Privatization Offer
Simcere Pharma, like many US-listed China biopharmas, has received a go-private offer from management, an offer that values Simcere at $503 million; Shanghai Pharma paid $72 million to purchase an additional 20% stake in Chiatai Qingchunbao Pharma, a Hangzhou maker of TCM products; New Jersey-based Catalent Pharma made two transactions that will increase its presence in China; Domain Associates formed a partnership with Elite Consulting, a consultant service for China life science, which will bring western products to China; Pathwork Diagnostics of California will collaborate with Kindstar to provide Pathwork’s cancer IVD kits in China; China has given the SFDA responsibility for monitoring the safety of the nation’s food supply; Sinovac Biotech reported positive top-line data from the Phase III clinical trial for its hand, foot and mouth vaccine; and BravoBio, a Shanghai vaccine startup, was named the 2013 BioSpectrum Asia Pacific Emerging Company of the Year. More details…. Stock Symbols: (NYSE: SCR) (SHA: 601607; HK: 02607) (NSDQ: SVA) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here